within Pharmacolibrary.Drugs.ATC.R;

model R03BA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.18,
    Cl             = 0.018333333333333333,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.004200000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fluticasone is a synthetic corticosteroid used as an anti-inflammatory and immunosuppressive agent, primarily for the management of asthma and allergic rhinitis. Administered via inhalation, it reduces airway inflammation. Widely approved and in clinical use globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after inhaled administration.</p><h4>References</h4><ol><li><p>Gillespie, M, et al., &amp; Steinfeld, J (2015). Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus Diskus and metered-dose inhalers. <i>Allergy and asthma proceedings</i> None None–None. DOI:<a href=&quot;https://doi.org/10.2500/.aap.2015.36.3889&quot;>10.2500/.aap.2015.36.3889</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26219638/&quot;>https://pubmed.ncbi.nlm.nih.gov/26219638</a></p></li><li><p>Gillespie, M, et al., &amp; Steinfeld, J (2015). Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler. <i>Allergy and asthma proceedings</i> 36(5) 365–371. DOI:<a href=&quot;https://doi.org/10.2500/aap.2015.36.3889&quot;>10.2500/aap.2015.36.3889</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26314817/&quot;>https://pubmed.ncbi.nlm.nih.gov/26314817</a></p></li><li><p>Anwar, MM, et al., &amp; Zaghary, WA (2015). Salmeterol Xinafoate. <i>Profiles of drug substances, excipients, and related methodology</i> 40 321–369. DOI:<a href=&quot;https://doi.org/10.1016/bs.podrm.2015.02.002&quot;>10.1016/bs.podrm.2015.02.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26051688/&quot;>https://pubmed.ncbi.nlm.nih.gov/26051688</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03BA05;
